Cargando…
Bone Age Maturation and Growth Outcomes in Young Children with CAH Treated with Hydrocortisone Suspension
BACKGROUND: Young children with congenital adrenal hyperplasia (CAH) require small doses (0.1-1.25 mg) of hydrocortisone (HC) to control excess androgen production and avoid the negative effects of overtreatment. The smallest commercially available HC formulation, before the recent US Food and Drug...
Autores principales: | Al-Rayess, Heba, Addo, O Yaw, Palzer, Elise, Jaber, Mu’taz, Fleissner, Kristin, Hodges, James, Brundage, Richard, Miller, Bradley S, Sarafoglou, Kyriakie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758402/ https://www.ncbi.nlm.nih.gov/pubmed/35047717 http://dx.doi.org/10.1210/jendso/bvab193 |
Ejemplares similares
-
Manipulation of Hydrocortisone Tablets Leads to Iatrogenic Cushing Syndrome in a 6-Year-Old Girl With CAH
por: Al-Rayess, Heba, et al.
Publicado: (2020) -
Application of Deep Neural Networks as a Prescreening Tool to Assign Individualized Absorption Models in Pharmacokinetic Analysis
por: Jaber, Mutaz M., et al.
Publicado: (2021) -
Individualized Absorption Models in Population Pharmacokinetic Analyses
por: Jaber, Mutaz M., et al.
Publicado: (2020) -
Sex non-specific growth charts and potential clinical implications in the care of transgender youth
por: Bomberg, Eric Morris, et al.
Publicado: (2023) -
SUN-251 Tanner Stage Adjustment of CDC Height Curves and Potential Clinical Applications
por: Addo, O. Yaw, et al.
Publicado: (2019)